The Pipeline

   
  ARMGO’s lead Rycal program (ARM036) is in Phase 2a clinical studies for heart failure, arrhythmias and CPVT. Excellent safety profile demonstrated in Phase 1 studies.

A second Rycal candidate (ARM210) is in preclinical development for Duchenne Muscular Dystrophy (DMD). Initial studies in mouse model of DMD (mdx) demonstrate improvements in voluntary exercise wheel activity and in specific muscle force, with no effect on wild-type mice.

A third effort targets CNS disorders including PTSD, Alzheimer’s Disease (AD), and Huntington’s Disease (HD). Mouse studies with RyR modulators support accumulating evidence that neuronal RyRs are intimately involved in the pathology of learning & memory disorders and of neurodegenerative diseases, and that restoration of normal intracellular calcium homeostasis is important to neuronal cell survival and normal function.
   
   
   
   
   
   

Current News



 

ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds   Link to Article


 

ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy   Link to Article


 

ARMGO Pharma, Inc. announces the appointment of Dr. Sapan Shah as CEO   Link to Article


 

Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59:1-30.   Link to Article


 

Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKlldelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A. 2010 Jun1;107(22):10274-9.   Link to Article


 

Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice.FEBS Lett. 2010 May 17;584(10):1956-65.   Link to Article


 

Betzenhauser MJ, Marks AR. Ryanodine Receptor channelopathies Pflugers Arch. 2010 Jul;460(2):467-80.   Link to Article


 

Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, Marks AR,Lacampagne A.- Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1559-64.4-9.   Link to Article


Prof. Andrew Marks presentation on, "Mechanism-Based Therapies for Heart Failure and Cardiac Arrhythmias" from the Henry Stewart Talks, Series, "Calcium Signalling: Regulation, Mechanisms, Effectors, Role in Disease and Recent Advances".
Link to Presentation